• MetaVia investor deck highlighted lead obesity candidate DA-1726, a once-weekly GLP-1R/GCGR dual agonist, with Phase 1 multi-ascending dose data showing 9.1% weight loss at 48 mg by Day 54 with no titration.
• Same dataset showed 3.8-inch waist reduction, 0.22 HbA1c decline, 23.7% drop in liver stiffness (VCTE), with mostly mild-to-moderate side effects.
• Program plan targets tolerability optimization with stepwise titration up to 64 mg, with Phase 1 Part 3 readout expected in Q4 2026.
• MASH asset vanoglipel (DA-1241), an oral GPR119 agonist, posted Phase 2a primary endpoint success in presumed MASH, with ALT down 22.8 U/L at Week 16, with significant HbA1c reductions at 100 mg versus placebo.
• Cash and cash equivalents were USD 13.7 million as of March 31, 2026, with no debt; capitalization table listed 5,164,370 common shares outstanding, 15,410,509 fully diluted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief on May 14, 2026, and is solely responsible for the information contained therein.